External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F20%3AA21028NJ" target="_blank" >RIV/61988987:17110/20:A21028NJ - isvavai.cz</a>
Alternative codes found
RIV/00216208:11150/21:10415036 RIV/00216208:11120/21:43920575 RIV/00179906:_____/21:10415036 RIV/00098892:_____/21:N0000088 and 2 more
Result on the web
<a href="https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.17074" target="_blank" >https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.17074</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/bjh.17074" target="_blank" >10.1111/bjh.17074</a>
Alternative languages
Result language
angličtina
Original language name
External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score
Original language description
Most patients with chronic lymphocytic leukaemia (CLL) are nowadays diagnosed without any symptoms and do not require therapy. A prognostic score identifying patients within this large group who are at high risk of disease progression would be highly beneficial. The recently published International Prognostic Score for Early asymptomatic patients (IPS-E) uses combination of absolute lymphocyte count (ALC) >15 x 10(9)/l, palpable lymphadenopathy, and unmutated immunoglobulin heavy-chain variable-region (IGHV)gene to predict the time to first-line therapy (TTFT). Patients at low, intermediate, and high risk had estimated 5-year TTFT of 8%, 28%, and 61%. We performed an external validation of the IPS-E score using an unselected, consecutive group of 130 Binet A patients. The 5-year TTFT was 11%, 36%, and 78% (C-statistic 0 center dot 74). Furthermore, we propose an alternative system (AIPS-E) using cytogenetic aberrations instead of palpable lymphadenopathy. This system yielded 5-year TTFT of 14%, 40%, and 72%. These results were externally validated in 388 Binet A patients from five Czech centres; the 5-year TTFT was 16%, 37%, and 80% (C-statistic 0 center dot 74). In conclusion, we have successfully validated the IPS-E score for patients with early stage CLL. In addition, we propose a modified scoring system, the AIPS-E, combiningIGHV, fluorescencein situhybridisation, and ALC.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
British Journal of Haematology
ISSN
0007-1048
e-ISSN
—
Volume of the periodical
193
Issue of the periodical within the volume
1
Country of publishing house
US - UNITED STATES
Number of pages
5
Pages from-to
133-137
UT code for WoS article
000567704900001
EID of the result in the Scopus database
—